An Imaging Study to Investigate the Distribution of GW842166X in the Brain.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00511524|
Recruitment Status : Completed
First Posted : August 6, 2007
Last Update Posted : August 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pain, Inflammatory||Drug: GW842166X Drug: [carbonyl-^11C]GW842166||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [11C]GW842166 in Healthy Subjects|
|Actual Study Start Date :||June 26, 2007|
|Primary Completion Date :||July 4, 2007|
|Study Completion Date :||July 4, 2007|
Experimental: Subjects receiving GW842166
Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive [carbonyl-^11C]GW842166.
GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.Drug: [carbonyl-^11C]GW842166
[carbonyl-^11C]GW842166 will b available as Intravenous solution.
- Rate at which the drug crosses from plasma to brain (ki)using images from the scan [ Time Frame: throughout the study ]
- Safety of drug [ Time Frame: after taking the drug pre-dose, 2hr, 4hr, 6hr, 10hr, 24hr, follow-up. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00511524
|GSK Investigational Site|
|Uppsala, Sweden, SE-753 23|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|